STOCK TITAN

Twist Bioscience - TWST STOCK NEWS

Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.

Overview of Twist Bioscience Corp

Twist Bioscience Corp is a pioneering synthetic biology company that has redefined the process of DNA synthesis using a proprietary semiconductor-based manufacturing platform. The company leverages innovative technology to produce high-quality synthetic DNA rapidly and cost-effectively. This breakthrough approach, characterized by synthesizing DNA on silicon rather than traditional plastic wells, positions Twist Bioscience as a disruptive force in the biotechnological landscape, driving advances in applications from biomedical research to industrial biotechnology.

Proprietary Technology and Manufacturing Process

At the heart of Twist Bioscience's operations is a state-of-the-art synthetic DNA manufacturing process. By employing a 10,000-well silicon platform, the company sidesteps the limitations inherent in conventional methods. The integration of semiconductor technology not only minimizes production inefficiencies but also ensures high throughput, which is crucial for applications requiring rapid gene synthesis and customization. This technical ingenuity underpins the company's ability to deliver:

  • High-quality oligonucleotides
  • Custom genes and genetic pathways
  • Complex chassis and complete genomes

Business Model and Revenue Generation

Twist Bioscience's business model is built on the dual pillars of technology licensing and direct sales. The company generates revenue by offering its synthetic DNA products to a wide range of customers including academic research institutions, biotechnology firms, and industrial manufacturers. Its cost-effective, rapid production capabilities allow clients to accelerate their research and development efforts, thereby reducing time-to-market for various applications. This operational efficiency is not only beneficial to its clients but also reinforces the company’s reputation for reliability and scalability in the synthetic biology market.

Market Position and Competitive Landscape

Operating in a highly specialized niche, Twist Bioscience has carved a unique position in the competitive synthetic biology ecosystem. The company differentiates itself through its disruptive manufacturing process and its capacity to produce synthetic biology tools at scale. In a market where reliability, speed, and cost-efficiency are paramount, Twist Bioscience’s strategic focus on overcoming production inefficiencies positions it as a significant player. Its technology challenges traditional paradigms and compels competitors to reconsider conventional manufacturing methods, thereby affirming its role as an innovator rather than a mere participant in the industry.

Applications and Industry Impact

The technology developed by Twist Bioscience has far-reaching implications across numerous sectors. In the field of biomedical research and personalized medicine, its rapid DNA synthesis paves the way for new diagnostics, targeted therapies, and advanced research into genetic disorders. Beyond healthcare, the company’s synthetic biology tools enable innovations in sustainable chemical production and improved agricultural practices, broadening the scope of applications into:

  • Biopharmaceutical research: Accelerating drug discovery and genetic screening.
  • Industrial biotechnology: Optimizing production processes for chemicals and materials.
  • Environmental monitoring: Developing in vivo diagnostics and biodetection solutions.

This multi-sector applicability underscores the versatility and transformative potential of Twist Bioscience's platform. By industrializing the engineering of biology, the company not only enhances research capabilities but also contributes significantly to sectors that rely on synthetic DNA for innovation and efficiency.

Operational Excellence and Research Ecosystem

Central to the success of Twist Bioscience is its commitment to operational excellence and continuous innovation. The company collaborates with a diverse ecosystem of researchers, academic institutions, and industrial partners, fostering an environment where technological breakthroughs are routinely translated into practical solutions. This collaborative approach ensures that every advancement in its manufacturing process is both rigorously validated and immediately deployable across a spectrum of research and industrial applications.

Scientific and Technical Expertise

Twist Bioscience is driven by a deep reservoir of scientific and technical expertise. The company’s team, comprised of leading experts in synthetic biology, semiconductor physics, and bioengineering, is instrumental in refining its technology and pushing the boundaries of what is possible in DNA synthesis. This expertise not only strengthens the company’s competitive position but also instills confidence in its ability to deliver reliable, high-quality synthetic biology products that meet the evolving needs of modern research and industry.

Integration into the Broader Biotechnology Landscape

The innovations from Twist Bioscience resonate well within the broader biotechnology and life sciences arenas. Its approach to DNA synthesis using semiconductor-based technology is widely recognized for its potential to revolutionize how genetic materials are produced and utilized. This integration of advanced material science with biotechnology exemplifies the cross-disciplinary innovation that is becoming increasingly important. Researchers and industrial partners alike appreciate the capacity for simultaneous high throughput and high precision, enabling a smoother transition from conceptual breakthroughs to tangible products.

Commitment to Quality and Reliability

Quality control and reliability are fundamental to Twist Bioscience’s operations. The company’s advanced manufacturing process ensures consistency and precision in synthetic DNA production. By employing robust quality assurance protocols throughout its production cycle, Twist Bioscience provides products that research institutions and industry players can depend upon for critical applications. This unwavering focus on quality not only supports current operational needs but also cements the company’s reputation as a trustworthy provider of synthetic biology tools.

Position within the Competitive Landscape

While the synthetic biology sector is competitive, Twist Bioscience’s distinctive approach allows it to maintain a unique market niche. Its semiconductor-based platform, coupled with the extensive scale and precision of production, sets it apart from more traditionally operated competitors. The company’s strategy of addressing the inherent inefficiencies of standard DNA synthesis methods resonates with clients looking for innovative solutions. This unique value proposition has enabled Twist Bioscience to develop a strong foothold in its primary markets, particularly in regions known for high research and development activity.

Conclusion

In summary, Twist Bioscience Corp represents a significant advancement in synthetic biology. Through its disruptive semiconductor-based synthetic DNA platform, the company not only accelerates research and industrial processes but also redefines the standards of cost efficiency and production quality. Its integrated approach, encompassing innovative technology, rigorous quality control, a collaborative research ecosystem, and a clear focus on operational excellence, makes it a compelling case study in modern biotechnology innovations. The breadth of its applications and its ability to deliver high-quality synthetic DNA at scale underscore its impact on the biotechnology industry and its sustained position in the competitive landscape.

Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) and Curio Genomics have announced a strategic collaboration to accelerate NGS (Next-Generation Sequencing) adoption in agricultural genomics. The partnership combines Twist's FlexPrep™ Ultra-High Throughput Library Preparation Kit with Curio's bioinformatics software platform.

The collaboration aims to overcome traditional barriers in NGS adoption for agrigenomics, where microarray workflows have dominated due to lower costs and familiarity. The integrated solution offers:

  • High-throughput genotyping capabilities for thousands of samples
  • Streamlined workflow with improved economics
  • Ability to generate high complexity libraries for low pass whole genome sequencing
  • All-in-one genotyping, marker discovery, and fine mapping
  • Compatibility with historical microarray data

The Twist FlexPrep™ UHT Kit features Normalization by Ligation™ technology, eliminating the need for individual DNA sample measurements and concentration adjustments, resulting in significant cost savings per sample.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.73%
Tags
none
-
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) has announced a -time offer for academic customers globally, providing Express Genes orders with expedited shipping in as few as four days at no additional cost. This initiative aims to support research institutions facing budget constraints while maintaining scientific progress.

The Express Genes offering includes:

  • Gene lengths ranging from 0.3kb to 5.0kb
  • NGS sequence verification with 100% accuracy
  • Flexibility in order volume
  • Options for cloning into catalog or custom vectors
  • Multiple delivery format options including tubes and plates

This move represents Twist's commitment to supporting academic research by eliminating premium charges for rapid turnaround times, helping institutions maximize their research budgets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.59%
Tags
none
-
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, has announced its executives' participation in upcoming investor conferences.

The schedule includes:

  • Emily Leproust, Ph.D., CEO and co-founder, and Adam Laponis, CFO, at the TD Cowen 45th Annual Health Care Conference on March 4 in Boston (fireside chat at 1:50 pm ET)
  • Patrick Finn, Ph.D., president and COO, and Adam Laponis, CFO, at the Leerink Global Biopharma Conference 2025 on March 11 in Miami (fireside chat at 9:20 am ET)
  • Patrick Finn and Adam Laponis at the Barclays Global Healthcare Conference 2025 on March 12 in Miami (fireside chat at 8:30 am ET)

All fireside chats will be webcast live through the investor relations section of the company's website and archived for 30 days after the events.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
conferences
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) has announced the granting of 123,024 equity awards to 32 newly hired employees as employment inducements. The awards consist of 72,394 restricted stock units (RSUs) and up to 50,630 performance stock units (PSUs).

The RSUs will vest over 48 months, with 25% vesting after one year and 1/16 vesting quarterly thereafter. The PSUs will vest based on performance metrics set by the Board's Compensation Committee, achievable by the end of fiscal 2027 at 50%-140% of target. Both are subject to continued employment.

These awards were granted under Twist's Amended and Restated Inducement Equity Incentive Plan, complying with Nasdaq Listing Rule 5635(c)(4) for new hires or those returning after non-employment periods.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
-
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST), a mid-cap life sciences company in the healthcare sector, has announced its financial results for the first quarter of fiscal 2025, which ended December 31, 2024. The company has scheduled a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss the results and provide a business update.

Participants interested in joining via telephone must register through the company's Investor Relations website. Detailed earnings report and investor presentation are available on the Events and Presentations page of Twist Bioscience's website. A webcast replay will be accessible for two weeks following the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.73%
Tags
-
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) has announced it will release its fiscal 2025 first quarter financial results for the period ended December 31, 2024, before market opening on February 3, 2025. The company will host a conference call and live audio webcast for analysts and investors at 8:00 AM Eastern Time on the same day.

Participants interested in joining via telephone must pre-register through the company's Investor Relations website. The financial results press release will be available on the company's website in the Investor Relations section. A webcast replay will be accessible for two weeks following the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.75%
Tags
conferences earnings
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST), a mid-cap life sciences company, has announced that CEO and co-founder Emily M. Leproust, Ph.D. will deliver a presentation at the 43rd Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 13, 2025, at 5:15 p.m. Pacific Time in San Francisco, California.

The event will be accessible via webcast through the company's investor relations website's 'Investor Calendar' section. Following the live presentation, a replay will remain available for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.22%
Tags
conferences
-
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) announced its financial results for Q4 and full year fiscal 2024 ended September 30, 2024. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss the results and provide a business update. Participants can access detailed earnings reports and investor presentations through the company's website. Those joining via telephone must register in advance to receive dial-in information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.31%
Tags
-
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST), a synthetic DNA manufacturer, announced its participation in the 7th Annual Evercore HealthCONx Conference. CEO and co-founder Emily M. Leproust, Ph.D., along with CFO Adam Laponis, will engage in a fireside chat on December 3, 2024, at 10:00 a.m. Eastern Time in Coral Gables, Florida. The event will be accessible via live webcast through the company's investor relations website, with a replay available for 30 days after the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.31%
Tags
conferences
Rhea-AI Summary

Twist Bioscience (NASDAQ: TWST) has announced new equity awards as employment inducements under Nasdaq Rule 5635(c)(4). The company granted 110,300 restricted stock units (RSUs) to 43 new employees and up to 37,500 performance stock units (PSUs) to VP Colby Souders. The RSUs vest over 48 months, with 25% vesting after one year and 1/16 vesting quarterly thereafter. The PSUs vest based on performance metrics for FY2024-2026, with potential earnings of 80%-150% of target, subject to continued employment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
none

FAQ

What is the current stock price of Twist Bioscience (TWST)?

The current stock price of Twist Bioscience (TWST) is $36.63 as of April 10, 2025.

What is the market cap of Twist Bioscience (TWST)?

The market cap of Twist Bioscience (TWST) is approximately 2.2B.

What is Twist Bioscience's core business?

Twist Bioscience focuses on synthetic biology by utilizing a proprietary semiconductor-based platform to synthesize high-quality DNA. Its core business involves manufacturing synthetic DNA for research, industrial biotechnology, and biomedical applications.

How does Twist Bioscience's technology differ from traditional methods?

The company synthesizes DNA on silicon rather than on conventional plastic plates, enabling cost-effective, rapid, and high-throughput production while overcoming common inefficiencies in traditional synthesis methods.

Which industries benefit from Twist Bioscience's products?

Industries ranging from biomedical research and personalized medicine to industrial biotechnology and sustainable chemical production benefit from their high-quality synthetic DNA products.

What are the primary products provided by Twist Bioscience?

Twist Bioscience produces a range of synthetic biology tools including oligonucleotides, genes, genetic pathways, chassis, and complete genomes, all synthesized using their advanced silicon-based platform.

How does the company's business model support its operations?

The company generates revenue through direct sales and technology licensing, offering high-quality synthetic DNA products that enhance research capabilities and industrial production efficiency.

What competitive advantages does Twist Bioscience hold in the synthetic biology market?

Their proprietary technology, which leverages semiconductor manufacturing techniques, allows them to produce DNA faster and more cost-effectively than traditional methods, positioning them uniquely in the competitive landscape.

Who are the primary customers of Twist Bioscience?

Twist Bioscience serves a diverse customer base including academic research institutions, biotechnology companies, and industrial manufacturers requiring reliable synthetic DNA production for various applications.

How does Twist Bioscience ensure the quality of its synthetic DNA products?

By integrating rigorous quality control protocols within its manufacturing process, the company ensures consistent and precise production, making its products dependable for critical research and industrial applications.
Twist Bioscience

Nasdaq:TWST

TWST Rankings

TWST Stock Data

2.16B
58.41M
2.16%
112.29%
15.59%
Diagnostics & Research
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO